Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells

  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 3 and
  • 1Email author
Contributed equally
BMC Cancer201616:602

https://doi.org/10.1186/s12885-016-2629-y

  • Received: 24 March 2016
  • Accepted: 26 July 2016
  • Published:
Open Peer Review reports

Abstract

Background

The S6 Kinase (S6K) proteins are some of the main downstream effectors of the mammalian Target Of Rapamycin (mTOR) and act as key regulators of protein synthesis and cell growth. S6K is overexpressed in a variety of human tumors and is correlated to poor prognosis in prostate cancer. Due to the current urgency to identify factors involved in prostate cancer progression, we aimed to reveal the cellular functions of three S6K isoforms–p70-S6K1, p85-S6K1 and p54-S6K2–in prostate cancer, as well as their potential as therapeutic targets.

Methods

In this study we performed S6K knockdown and overexpression and investigated its role in prostate cancer cell proliferation, colony formation, viability, migration and resistance to docetaxel treatment. In addition, we measured tumor growth in Nude mice injected with PC3 cells overexpressing S6K isoforms and tested the efficacy of a new available S6K1 inhibitor in vitro.

Results

S6Ks overexpression enhanced PC3-luc cell line viability, migration, resistance to docetaxel and tumor formation in Nude mice. Only S6K2 knockdown rendered prostate cancer cells more sensitive to docetaxel. S6K1 inhibitor PF-4708671 was particularly effective for reducing migration and proliferation of PC3 cell line.

Conclusions

These findings demonstrate that S6Ks play an important role in prostate cancer progression, enhancing cell viability, migration and chemotherapy resistance, and place both S6K1 and S6K2 as a potential targets in advanced prostate cancer. We also provide evidence that S6K1 inhibitor PF-4708671 may be considered as a potential drug for prostate cancer treatment.

Keywords

  • mTOR
  • S6K
  • Cancer

Background

Prostate cancer is the second most frequently diagnosed cancer among men worldwide and the first in developed countries [1]. Although prostate cancer has a good prognosis in its early stages, with nearly all men living at least five years after diagnosis, the 5-year survival rate decreases drastically, to less than 30 %, when it reaches advanced and metastatic stages. This reveals the current urgency to identify factors involved in prostate cancer progression [2].

The S6K proteins are members of the AGC family of serine/threonine kinases and one of the main downstream effectors of the mammalian Target Of Rapamycin (mTOR) protein. In mammals, the S6K family is composed of several proteins encoded by two different genes: RPS6KB1 and RPS6KB2. Due to the alternative use of AUG start codons, each S6K gene generates two distinct isoforms: p70-S6K1, p85-S6K1, p54-S6K2 and p56-S6K2 [3, 4]. More recently, it has been discovered that the splicing factor SF2/ASF acts on S6K1 gene promoting the expression of a novel isoform, p31-S6K1, that lacks most of its catalytic domain [5]. Once activated by mTOR, the S6K proteins are able to phosphorylate targets as rpS6 (ribosomal protein S6), eIF4B (eukaryotic translation Initiation Factor 4B) and eEF2K (eukaryotic Elongation Factor 2 Kinase), promoting protein synthesis and cell growth [3].

Due to their key role in regulating cell growth and proliferation, several studies have shown that S6K genes are amplified in a variety of human tumors, including prostate cancer [69]. In fact, S6K is not only overexpressed in prostate cancer, but also is related to its progression [10], making it a potential target for prostate cancer treatment. Despite the high homology shared between S6K1 and S6K2, evidence shows that they might play some distinct cellular functions [11]. Global expression profiles for breast tumors harboring high levels of S6Ks recently revealed that only a few set of genes strongly correlated to both S6K1 and S6K2, suggesting that each protein play different functions in tumorigenesis and cancer progression [12]. However, these differences have been poorly investigated and the major understanding about S6Ks roles in cancer is from studies restricted to p70-S6K1 [1319].

Here, we aimed to reveal the cellular functions of three S6K isoforms–p70-S6K1, p85-S6K1 and p54-S6K2–in prostate cancer, as well as their potential as therapeutic targets. We show that all isoforms were important for increasing prostate cancer cells proliferation, migration and resistance to docetaxel in vitro. Moreover, S6Ks presented an important effect for tumor progression in vivo. Finally, we demonstrate the potential use of an available S6K1 inhibitor.

Methods

Cell culture

Human metastatic prostate cancer cell line PC-3 and the luciferase expressing cell line PC3-luc were cultured in Ham’s F12 (Thermo Scientific) supplemented with 10 % FBS (fetal bovine serum) and 1 % penicillin/streptomycin (Thermo Scientific). Human metastatic prostate cancer cell line DU-145 was cultured in Dulbecco’s Modified Eagle Medium (Thermo Scientific) supplemented with 10 % FBS and 1 % penicillin/streptomycin (Thermo Scientific). Cells were maintained at 37 °C in a humidified atmosphere containing 5 % carbon dioxide.

Transfection of human cells

Cells were seeded 24 h before transfection. Transfection was performed with Lipofectamine and PLUS reagents (Thermo Scientific). Briefly, DNA and PLUS reagent were diluted in serum free medium and incubated for 15 min at room temperature. Lipofectamine was then diluted in serum free medium, mixed to the DNA solution and incubated for 15 min at room temperature. The cells were washed with serum free medium and the DNA/Lipofectamine complexes were added. After 3 h, the medium was exchanged for medium containing 10 % FBS and the cells incubated for 24 to 72 h.

Virus production

Lentivirus and retrovirus preparations were generated at Viral Vector Laboratory, Brazilian National Laboratory for Biosciences, Brazilian Center for research in Energy and Materials. Virus were titrated by puromycin selection and counting forming colonies.

S6Ks RNAi knockdown and overexpression

Lentiviruses expressing shRNA targeting S6K1 and S6K2 human mRNA were produced using pLK0.1 vector (Sigma Aldrich). S6K1 shRNA sequence (TRCN0000022904) has been published before [20]. For S6K2 knockdown, we tested two different shRNA sequences: TRCN0000010539 and TRCN0000199878, identified respectively as shRNA-S6K2-1 and shRNA-S6K2-2. For the control, we used a pLKO.1 plasmid (SHC002) that targets no mammalian genes and was identified as shC.

The retroviral plasmid pBABE-puro was used to perform S6K overexpression. Fragments of S6K isoforms were cloned into BamHI/SalI restriction sites and retroviral-mediated gene transfer was performed as described previously [21, 22].

Viral transduction

PC3-luc cells were seeded at a density of 8 × 103 cells/well in 96-well plates and incubated for 24 h. Virus particles were added at a low multiplicity of infection (MOI) of 0.3 for lentiviruses and 0.1 for retroviruses in the presence of 8 μg/ml of polybrene. Cell culture medium was changed 24 h after transduction and cells were then selected with 1 μg/mL of puromycin until complete death of control cells.

Western blotting

Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Nitrocellulose membranes were blocked in a solution of TBS containing 5 % nonfat dry milk and 0,1 % Tween-20 for 2 h with constant agitation. After blocking, the membranes were incubated with anti-p70-S6K1 (Cell Signaling), anti-S6K2 (Bethyl) or anti-α-tubulin (Calbiochem) antibodies overnight at 4 °C. Membranes were washed with TBS-T (3 times for 15 min) and incubated with horseradish peroxidase-conjugated secondary antibodies (Millipore) for 1 h at room temperature with constant agitation. Bands were visualized using the ECL kit (GE Healthcare). Band densitometry was measured using ImageJ software.

MTT viability assay

PC3-luc cells with stable S6K knockdown or overexpression were seeded at a density of 104 cells/well in 96-well plates and incubated for 24, 48 and 72 h. Following each period of incubation, 12 mM of 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) was added to each well for 4 h. The culture medium was aspirated and the formazan crystals were solubilized with a solution of HCl 1 N:isopropanol (1:25) for 15 min. The optical density of the plates was measured at 570 nm.

Migration assay

PC3-luc cells with stable S6K knockdown or overexpression were seeded at a density of 5 × 105 cells/well in 24-well plates and incubated until confluence. After that, cell monolayers were scratched in the middle of the wells with a p200 pipette tip and the culture medium was replaced by serum free media [23]. Scratch area was analyzed under light microscope and images were captured right after the scratch (0 h) and after incubation for 24 and 48 h. The scratch area was quantified using ImageJ software.

Colony-forming assay

Cells were plated at low density (5 × 102 cells / plate) in 60 mm plates and transfected with plasmids pFLAG-p70-S6K1, - p85-S6K1, - p54-S6K2 or pFLAG (empty vector). The cells were incubated at 37 ° C for 10 days. For staining, the cells were washed with PBS and stained with 1 mL of methylene blue dye (3 %) for 30 min. The plates were washed and colonies were counted, excluding colonies smaller than 1 mm in diameter.

Proliferation assay

Cells were plated in 24-well plates, transfected with plasmids pFLAG- p70-S6K1, - p85-S6K1, - p54-S6K2 or pFLAG (empty vector) and then incubated for up to 6 days with 10 % FBS at 37 ° C. Counts were performed using automated cell counter on days 2, 4 and 6 after transfection.

Docetaxel resistance assay

Docetaxel resistance assay was performed as previously described by Uzoh et al. [24], with slight modifications. PC3-luc cells with stable S6K knockdown or overexpression were seeded at a density of 8 × 105 cells/well in 24-well plates and incubated for 24 h. The culture medium was then replaced by serum free media and the plates were incubated for 24 h. Afterwards, cells were treated with 30 nM of docetaxel (Sigma Aldrich) for 48 h, which was firstly dissolved in DMSO and then diluted in serum free media. Control cells received serum free media and the vehicle. The number of living cells was counted using an automated cell counter (Thermo Scientific) after Trypan Blue staining.

In vivo tumor formation assay

All animal experiments were performed in accordance to the internal committee of ethics in animal research of the Faculty of Medicine of the University of São Paulo. One million PC3-luc cells with stable S6K overexpression or knockdown were injected subcutaneously into 7 male athymic Nude mice per group. Tumor growth was measured about three times per week using a caliper rule and calculated according to the formula: ½ × (larger diameter) × (smaller diameter) 2 until they reached the maximum volume of 1000 mm3.

Treatment of cells with PF4708671

PC3 and DU145 cells were treated with 10 μM of S6K1 inhibitor PF4708671 [25], by changing medium containing the drug every day, until 6 days. The drug was first dissolved in DMSO and then diluted in medium with serum.

Statistical analysis

Values presented are means ± standard deviation (SD). Statistical analyzes were assessed by one-way and two-way analysis of variance (ANOVA) followed by Bonferroni’s post-test and performed using GraphPadPrism 5 software. p-values < 0.05 were considered significant (*p < 0.05; **p < 0.01; ***p < 0.001).

Results

S6K knockdown inhibits cell viability

S6Ks stable knockdown and overexpression in PC3-luc cells were confirmed by western blotting (Fig. 1 a-b). Although some reports indicate that the knockout of one S6K isoform in vivo may cause a compensatory upregulation of the other [26, 27], we observed a slight compensatory effect by S6K1 in the S6K2-1 knockdown in vitro. To investigate the effects of S6Ks knockdown or overexpression in PC3-luc prostate cancer cell line viability, we performed the MTT assay. S6K2 knockdown significantly reduced cell viability in all time periods (Fig. 1c). Similar inhibition was observed in both S6K2 shRNA sequences tested. S6K1 knockdown showed significant reduction only on the second day and appeared to be less relevant than S6K2. However, the overexpression of all three S6K isoforms significantly raised cell viability (Fig. 1d).
Fig. 1
Fig. 1

S6Ks increase cell viability in PC3-luc cells. Western blotting analyses of S6K isoforms expression modulation in human prostate cancer cell line PC3-luc transduced with a lentiviruses pLKO.1-shRNAs against S6K1 and S6K2 and b with retroviruses carrying pBABE construction. S6K1 antibody detects both p85-S6K1 and p70-S6K1 proteins. c Relative cell viability in PC3-luc cells with knockdown of S6Ks isoforms and d in PC3-luc cells overexpressing S6Ks isoforms. Cells were seeded in 96-well plates at a density of 104 cells/well. After 24, 48 and 72 h, cells were treated with MTT (12 mM) for 4 h and absorbance was measured at 570 nm. *p < 0.05, **p < 0.01, ***p < 0,001, n = 3

S6K knockdown inhibits cell migration

Next we investigated if S6K isoforms also impacted the migration capacity of prostate cancer cells (Fig. 2). Both S6K1 and S6K2 knockdown resulted in a significant decrease in cell migration. Again, no difference was observed between both S6K2 shRNA sequences. In contrast, as expected, the overexpression of S6K isoforms significantly increased scratch area closure.
Fig. 2
Fig. 2

S6Ks increase migration of PC3-luc cells. Cells were seeded in 24-well plates at a density of 5x104 cells/well and incubated until confluence. A scratch was made in the cells monolayer with a pipette tip and cells were washed and incubated in serum free media. The scratch area was measured at 0 (time of scratch), 24 and 48 h. a Migration assay in PC3-luc cells with knockdown of S6Ks isoforms. a, b Scratch relative area of PC3-luc cells overexpressing S6Ks isoforms. c, d Representative images of scratch area taken at 0, 24 and 48 h of PC3-luc cells with S6K knockdown and overexpression, respectively. *p < 0.05, **p < 0.01, ***p < 0,001, n = 3

S6K2 expression is related to docetaxel sensitivity

We investigated whether S6Ks might play a role in prostate cancer chemotherapy resistance. We treated PC3-luc with docetaxel, a chemotherapeutic drug widely used in hormone-refractory prostate cancer treatment [28]. As expected, docetaxel treatment reduced the number of living cells in all groups when compared to untreated cells (Fig. 3). However, the reduction was significantly greater in cells with S6K2 knockdown (Fig. 3a). When overexpressed, all S6Ks isoforms showed significantly less reduction in the number of living cells than the GFP control (Fig. 3b).
Fig. 3
Fig. 3

p54-S6K2 knockdown increases cell death in response to docetaxel in PC3-luc cells. Cells were seeded in 24-well plates at a density of 8x104 cells/well. After 24 h, cells were subjected to serum free media conditions for 24 h and then treated for 48 h with docetaxel (30 nM). Living cells were counted and expressed as percentages. Results presented are means of two independent experiments. Each experiment was performed in triplicates. SMF: serum free media; DTX: docetaxel. *p < 0.05, **p < 0.01, ***p < 0,001, n = 2

S6K overexpression enhances tumor growth in Nude mice

After having determined that S6Ks are involved in some prostate cancer features in vitro, we investigated their tumorigenic ability in vivo, by injecting PC3-luc cells overexpressing S6K isoforms or knocked down for S6K1 or S6K2 subcutaneously into the flanks of male athymic Nude mice and measuring tumor growth. Tumors started growing about 10 days after injection and from this moment tumor volume was assessed for about 30 days. Animals injected with PC3-luc cells overexpressing S6K isoforms, particularly p70-S6K1, showed significantly greater tumor growth than those injected with cells harboring GFP control (Fig. 4a). Conversely, animals injected with PC3-luc cells containing the knockdown of S6K1 or S6K2 presented significantly reduced tumor growth in vivo (Fig. 4b).
Fig. 4
Fig. 4

S6K isoforms increase tumor growth in Nude mice. a Tumor growth curves of Nude mice injected subcutaneously with PC3-luc cells overexpressing S6K isoforms (p70-S6K1, p85-S6K1 and p54-S6K2) or GFP control. Tumors measurements began 14 days after injection and proceeded until day 44. b Tumor growth curves of Nude mice injected subcutaneously with PC3-luc cells with knockdown for S6K1 and S6K2 isoforms or shRNA control. Tumors measurements began 11 days after injection and proceeded until day 39. * p < 0,05, ** p < 0,01 e *** p < 0,001; n = 7

S6K1 inhibitor PF47086701 decreases proliferation and migration of PC3 prostate cancer cell line

To check the efficiency of S6K1 inhibitor in prostate cancer cells DU145 and PC3, western blotting was performed in order to evaluate the S6 phosphorylation status (Fig. 5a). Rapamycin was used in this experiment as control. PF47086701 was able to reduce S6 phosphorylation in both DU145 and PC3 cells lines, although its effect was more discrete when compared to rapamycin, which completely abolished S6 phosphorylation (Fig. 5a). In a proliferation assay, DU145 and PC3 cells were plated and counted after treatment with PF47086701 (10 μM). Only PC3 cells showed a decrease in the number of cells when treated with the inhibitor of S6K1 (Fig. 5b). In a migration assay, the scratched monolayers were treated with serum-free medium and PF4708671 (10 μM) daily. The areas were measured within 48 h after the scratch. PC3 cells showed a significant decrease in migration compared to control in the presence of S6K1 inhibitor (Fig. 5c).
Fig. 5
Fig. 5

S6K1 inhibitor PF47086701 inhibits cell proliferation and migration of prostate cancer cells. a Western blotting analysis of PF47086701 efficiency. b Proliferation assay in DU145 and PC3 cell lines treated with PF47086701. c Scratch relative area of DU145 and PC3 cells treated with PF47086701. *p < 0.05, **p < 0.01, ***p < 0,001, n = 3

To compare the effects of S6Ks overexpression in DU145 and PC3 cell lines, we transiently transfected them with pcDNA-FLAG vector carrying p70-S6K1, p85-S6K2 and p54-S6K2 genes (Additional file 1: Figure S1A). The results show that in both cell lines p85-S6K1 isoform enhanced the cellular proliferation (Additional file 1: Figure S1B). Colony formation assay also indicated that cells with overexpression of p85-S6K1 showed increased number of colonies (Additional file 1: Figure S1C). These results point an important role of S6K1 isoform in prostate cancer.

Discussion

S6K proteins are well known effectors of mTOR and major regulators of protein synthesis and cell growth [4]. They are found overexpressed in several human tumors and are correlated with poor prognosis [10, 29, 30]. It has already been reported that silencing mTOR decreases prostate cancer cell proliferation and colony formation [31]. Here we show that S6Ks overexpression enhances proliferation and clonogenic ability of human metastatic prostate cancer cell lines. Next, we evaluated the effects of S6K knockdown and overexpression on prostate cancer cells viability, migration and resistance to decetaxel treatment.

Recently, Du et al. (2014) showed that mTOR knockdown by lentivirus mediated shRNA significantly reduces cell viability in prostate cancer metastatic cell lines LNCaP and C4-2B. As expected, we not only observed that S6K knockdown produced similar effects on PC3-luc cells, but also reported an expressive increase in cell viability determined by S6K overexpression. Interestingly, we found that although the effects of p70-S6K1 and p54-S6K2 overexpression were quite similar, S6K1 knockdown had no impact on cell viability. A possible explanation is that S6K1 knockdown is compensated by S6K2 isoform, masking the effects on cell viability.

We also reported that S6K expression is positively related to an increase in PC3-luc cells migration. Since tumor cell motility is a fundamental part of the metastatic cascade, our data imply an involvement of all S6K isoforms in raising metastatic capability of PC3-luc cells. In fact, p70-S6K1 has been described as a regulator of cell motility [32] and several human tumorigenic cell lines, such rhabdomyosarcoma (Rh1 and Rh30), breast cancer (MDA-MB-468) and cervical adenocarcinoma (HeLa) were shown to alter their motility and invasion capabilities in response to rapamycin and these phenomena were regulated by mTOR through S6K1 and 4E-BP1 [33]. p70-S6K1 can directly bind to F-actin and is localized at the actin arc of migrating cells [34, 35]. In ovarian cancer cells, p70-S6K1 regulates cytoskeleton organization and cell migration by activating the GTPases Rac1 and Cdc42, involved, respectively, in dictating forward movement and migration’s direction [34]. Indeed, p70-S6K1 knockdown ovarian cancer cells migrate less and exhibit reduced directional persistence [34]. Our results show that S6K1 promotes cell migration in PC3-luc cell line and that S6K2 is also involved in the regulation of this process.

S6K2 knockdown was also effective in raising docetaxel sensitivity in PC3-luc cells. It has been reported that S6K2 is activated by FGF-2 (Fibroblast Growth Factor-2) and phosphorylates PDCD4, a repressor of the translation of anti-apoptotic proteins such as XIAP and Bcl-xL [36]. PDCD4 phosphorylation by S6K2 causes its degradation and leads to survival and chemoresistance in lung cancer cells [36, 37]. Although studies relating S6Ks to chemotherapy resistance are scarce, several reports indicate that mTOR is involved in drug resistance against chemotherapy [3843]. Niu et al. [44] showed that mTOR inhibition by rapamycin raises apoptosis and sensitivity to docetaxel induced cytotoxity in several human metastatic lung cancer cell lines treated with different concentrations of docetaxel. Treatment with NVP-BEZ235-a PI3K/mTOR dual inhibitor–was able to sensitize human castration resistant prostate cancer cell lines C4-2 and C4-2AT6 resistant to docetaxel, indicating that mTOR inhibition can even overcome chemoresistance in castration resistant prostate cancer [45]. However, the specific role of mTOR in developing chemotherapy resistance is still poorly understood, yet of current clinical importance. Here, we show that docetaxel resistance in PC3-luc cell line may be at least in part mediated by S6K, especially p54-S6K2.

The oncogenic role of S6K was also confirmed in vivo. The overexpression of all S6K isoforms was able to enhance tumor formation in Nude mice and the knockdown of S6Ks isoforms was able to reduce tumor growth in vivo. This result corroborates to Du et al. [31], that demonstrated that Nude mice injected with human metastatic prostate cancer cell line C4-2B with mTOR knockdown presented a greater reduction in tumor volume when compared to control group. As it was shown that p70-S6K1 played a major role in increasing tumor formation in vivo, we decided to test the effectiveness of a novel S6K1 inhibitor, PF-4708671.

We demonstrated that targeting S6K1 with PF-4708671 provided reduced cell migration and proliferation in PC3 cells, but had no effect on DU145 cell line (Fig. 5). A possible explanation for this difference is that PC3 cells, but not DU145, are PTEN null. PTEN deletion leads to increased PI3K activity and therefore hyperactivation of mTORC1/S6K [46]. Thus, it is possible that the mechanisms inducing proliferation and migration in PC3 cells are more related to S6K activity than in DU145 cells and, therefore, more susceptible to PF-4708671 effect.

PF-4708671 is a cell-permeable piperazinyl-pyrimidine compound that specifically inhibits p70-S6K1 with a Ki of 20 nM and IC50 of 160 nM and exhibits no significant inhibition of S6K2 or other AGC kinases [25], which may explain the reduced effect to abolish S6 phosphorylation comparing to rapamycin (Fig 5a), since S6K2 may still act on S6 protein. Due to its recent development, there are only a few reports regarding PF-4708671 use in anti-cancer therapies [3, 25]. S6K1 inhibition by PF-4708671 was shown to sensitize resistant colorectal cancer cells to selumetinib [47], to decrease cell migration and invasion of MDA-MB-231 human breast cancer cell line [48] and to inhibit cell invasion and proliferation in human lung cancer cell lines and tumorigenesis in Nude mice [49]. Hence, our results ratify that PF-4708671 might be a novel potential adjuvant in metastatic prostate cancer drug treatment.

Conclusions

In summary, our study demonstrated that S6K overexpression enhances cell viability, migration and resistance to docetaxel in PC3-luc prostate cancer cell line and tumor volume in Nude mice. In addition, we showed that the often neglected S6K2 is also involved in these processes and might be a potential target to restore docetaxel sensitivity in advanced prostate cancer. The S6K1 inhibitor PF-4708671 was particularly effective in reducing cell migration of PC3 and DU145 cell lines, suggesting that it could represent a possible adjuvant to prevent prostate cancer progression to its advanced state.

Abbreviations

eEF2K, eukaryotic Elongation Factor 2 Kinase; eIF4B, eukaryotic translation Initiation Factor 4B; FBS, fetal bovine serum; mTOR, mammalian Target Of Rapamycin; MTT, 12 mM of 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide; rpS6, ribosomal protein S6; S6K, S6 Kinase.

Declarations

Acknowledgements

We thank prof. Bryan Strauss from the Cancer Institute of São Paulo for gently revise the manuscript. We thank prof. Marcio Torsoni, prof. Adriana Torsoni and prof. Marciane Milanski from Laboratory of Disorders of Metabolism (LabDiMe), and all of its members, from University of Campinas, for all experimental support.

Funding

This work was supported by the São Paulo Research Foundation (FAPESP), grant number 2012/13558-7 and fellowships from FAPESP and CNPq.

Authors’ contributions

CLA participated in the viruses transductions, viability, migration, docetaxel resistance and in vivo experiments and drafted the manuscript. LBF participated in the proliferation, migration and S6K1 inhibitor experiments and performed initial standardization of protocols. RET performed and coordinated in vivo experiments and participated in design of experiments. MRT participated in initial cloning. ICBP participated in initial cloning. MCB performed and coordinated viruses production and participated in design of experiments. FMS conceived of the study and participated in its design and coordination. All authors have read and approved this manuscript.

Availability of data and materials

Datasets supporting the conclusions of this article are available after publishing in the FigShare repository.

Competing interests

The authors declare that they have no competing interests.

Consent to publish

Not applicable.

Ethics approval and consent to participate

All animal experiments were performed in accordance to guidelines of the internal committee of ethics in animal research of the Faculty of Medicine of the University of São Paulo and approved by the same.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Disorders of Metabolism, School of Applied Sciences, University of Campinas, R. Pedro Zaccaria, 1300, sala LA 421, 13484-350 Limeira, São Paulo, Brazil
(2)
Viral Vector Laboratory, Center for Translational Investigation in Oncology/LIM24, Cancer Institute of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil
(3)
Brazilian Biosciences National Laboratory, Brazilian National Center for Research in Energy and Materials, Campinas, São Paulo, Brazil

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.View ArticlePubMedGoogle Scholar
  2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.View ArticlePubMedGoogle Scholar
  3. Tavares MR, Pavan ICB, Amaral CL, Meneguello L, Luchessi AD, Simabuco FM. The S6K protein family in health and disease. Life Sci. 2015;131:1–10.View ArticlePubMedGoogle Scholar
  4. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2012;441(1):1–21.View ArticlePubMedGoogle Scholar
  5. Karni R, De Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14(3):185–93.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006;66(11):1203–12.View ArticlePubMedGoogle Scholar
  7. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008;27(0 2):S43–51.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Yoshida S, Matsumoto K, Arao T, Taniguchi H, Goto I, Hanafusa T, et al. Gene Amplification of Ribosomal Protein S6 Kinase-1 and–2 in Gastric Cancer. Anticancer Res. 2013;33(2):469–75.PubMedGoogle Scholar
  9. Savinska LO, Lyzogubov VV, Usenko VS, Ovcharenko GV, Gorbenko ON, Rodnin MV, et al. Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors. Eksp Onkol. 2004;26(1):24–30.PubMedGoogle Scholar
  10. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008;118(9):3051–64.PubMedPubMed CentralGoogle Scholar
  11. Pardo OE, Seckl MJ. S6K2: The Neglected S6 Kinase Family Member. Frontiers in Oncology. 2013;3:191.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Karlsson E, Magić I, Bostner J, Dyrager C, Lysholm F, Hallbeck A-L, et al. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis. PLoS One. 2015;10(12):e0145013.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, et al. Requirement of Androgen-Dependent Activation of Protein Kinase Cζ for Androgen-Dependent Cell Proliferation in LNCaP Cells and Its Roles in Transition to Androgen-Independent Cells. Mol Endocrinol. 2006;20(12):3053–69.View ArticlePubMedGoogle Scholar
  14. Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, et al. Regulation of androgen receptor transactivity and mTOR–S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate. 2010;70(8):866–74.PubMedGoogle Scholar
  15. Park J-Y, Park J-W, Suh S-I, Baek W-K. d-Glucosamine down-regulates HIF-1α through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009;382(1):96–101.View ArticlePubMedGoogle Scholar
  16. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms. Clin Cancer Res. 2004;10(24):8421–5.View ArticlePubMedGoogle Scholar
  17. Ip CKM, Wong AST. Exploiting p70 S6 kinase as a target for ovarian cancer. Expert Opin Ther Targets. 2012;16(6):619–30.View ArticlePubMedGoogle Scholar
  18. Baba HA, Wohlschlaeger J, Cicinnati VR, Hilgard P, Lang H, Sotiropoulos GC, et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. 2009;29(3):399–405.View ArticlePubMedGoogle Scholar
  19. Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 2007;251(1):105–13.View ArticlePubMedGoogle Scholar
  20. Carnevalli LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, Gandin V, et al. S6K1 Plays a Critical Role in Early Adipocyte Differentiation. Dev Cell. 2010;18(5):763–74.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Bajgelman MC, Costanzi-Strauss E, Strauss BE. Exploration of critical parameters for transient retrovirus production. J Biotechnol. 2003;103(2):97–106.View ArticlePubMedGoogle Scholar
  22. Strauss BE, Patrício JR, De Carvalho ACV, Bajgelman MC. A lentiviral vector with expression controlled by E2F-1: A potential tool for the study and treatment of proliferative diseases. Biochem Biophys Res Commun. 2006;348(4):1411–8.View ArticlePubMedGoogle Scholar
  23. Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protocols. 2007;2(2):329–33.View ArticlePubMedGoogle Scholar
  24. Uzoh CC, Holly JMP, Biernacka KM, Persad RA, Bahl A, Gillatt D, et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 2011;104(10):1587–93.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Pearce Laura R, Alton Gordon R, Richter Daniel T, Kath John C, Lingardo L, Chapman J, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010;431(2):245–55.View ArticlePubMedGoogle Scholar
  26. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. S6K1 (/)/S6K2 (/) Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway. Mol Cell Biol. 2004;24(8):3112–24.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70 (s6k)/p85 (s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 1998;17(22):6649–59.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Therapeutic Advances in Medical Oncology. 2012;4(6):329–40.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Man Ip CK, Yung S, Chan T-M, Tsao S-W, Tsai Wong AS. p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/β1 integrin signaling activation. Oncotarget. 2014;5(19):9133–49.View ArticlePubMed CentralGoogle Scholar
  30. Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 2013;15(5):R96.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Du Y-F, Long Q-Z, Shi Y, Liu X-G, Li X-D, Zeng J, et al. Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth. Int J Clin Exp Pathol. 2014;7(3):923–31.PubMedPubMed CentralGoogle Scholar
  32. Berven LA, Crouch MF. Cellular function of p70S6K: A role in regulating cell motility. Immunol Cell Biol. 2000;78(4):447–51.View ArticlePubMedGoogle Scholar
  33. Zhou H, Huang S. Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis. Curr Protein Pept Sci. 2011;12(1):30–42.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Ip CKM, Cheung ANY, Ngan HYS, Wong AST. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011;30(21):2420–32.View ArticlePubMedGoogle Scholar
  35. Berven LA, Willard FS, Crouch MF. Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res. 2004;296(2):183–95.View ArticlePubMedGoogle Scholar
  36. Liwak U, Thakor N, Jordan LE, Roy R, Lewis SM, Pardo OE, et al. Tumor Suppressor PDCD4 Represses Internal Ribosome Entry Site-Mediated Translation of Antiapoptotic Proteins and Is Regulated by S6 Kinase 2. Mol Cell Biol. 2012;32(10):1818–29.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCɛ, B-Raf and S6K2. EMBO J. 2006;25(13):3078–88.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Jiang B-H, Liu L-Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat. 2008;11(3):63–76.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M, et al. Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res. 2014;26(5):564–72.PubMedPubMed CentralGoogle Scholar
  40. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Wang Z, Huang Y, Zhang J. Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy. Cell Mol Biol Lett. 2014;19(2):233.View ArticlePubMedGoogle Scholar
  42. Yardley DA. Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer. 2013;7:7–22.PubMedPubMed CentralGoogle Scholar
  43. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014;111(1):409–14.View ArticlePubMedGoogle Scholar
  44. Niu H, Wang J, Li H, He P. Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011;30(1):28.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer. J Urol. 2014;191(1):227–34.View ArticlePubMedGoogle Scholar
  46. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27(41):5527–41.View ArticlePubMedGoogle Scholar
  47. Grasso S, Tristante E, Saceda M, Carbonell P, Mayor-López L, Carballo-Santana M, et al. Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation. Neoplasia (New York, NY). 2014;16(10):845–60.View ArticleGoogle Scholar
  48. Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang S-S, Hsu M-C, et al. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res. 2014;6(4):361–76.PubMedPubMed CentralGoogle Scholar
  49. Qiu Z-X, Sun R-F, Mo X-M, Li W-M. The p70S6K Specific Inhibitor PF-4708671 Impedes Non-Small Cell Lung Cancer Growth. PLoS One. 2016;11(1):e0147185.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement